I wasn't expecting much today but all these small moves add...

I wasn't expecting much today but all these small moves add up.

While our HCV programs are in their infancy, maybe we can catch some of that HCV bubble if we move to the US.

We'll have a lead candidate for our NN in June. For the non-NN side we have power to destroy Biocrysts program (which is about to start clinical trials at the end of the year). If we have power to destroy something then we can control it lol. If US investors liked Biocrysts HCV program so much that it bid up it's MC by $100M then by extension our patent has the goods.

To illustrate the HCV bubble, Novartis handed over upfront $30 million for a pre-clinical HCV candidate.

Invivo Blog